Emerging roles for PAX8 in ovarian cancer and endosalpingeal development

Gynecologic Oncology

Volumn 104, Issue 2, 2007, Pages 331-337

  Bowen, Nathan J ^a,b   Logani, Sanjay ^c   Dickerson, Erin B ^a,b   Kapa, Laura B ^a   Akhtar, Mariam ^a   Benigno, Benedict B ^b   McDonald, John F ^a,b  

^a GEORGIA INSTITUTE OF TECHNOLOGY   (United States)

^b Ovarian Cancer Institute   (United States)

^c EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Apoptosis; Development; Endosalpingeal; Epithelial ovarian cancer; Paired box gene

Indexed keywords

TRANSCRIPTION FACTOR PAX8;

ARTICLE; CELL NUCLEUS; CELL PROLIFERATION; CILIATED EPITHELIUM; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTHESIS; IMMUNOBLOTTING; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; OVARY CANCER; OVARY CYST; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SECRETORY CELL; UTERINE TUBE; UTERINE TUBE MUCOSA;

FALLOPIAN TUBES; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; OVARIAN NEOPLASMS; OVARY; PAIRED BOX TRANSCRIPTION FACTORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 33846336161     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.08.052     Document Type: Article

References (45)

1. Auersperg N., Wong A.S., Choi K.C., Kang S.K., and Leung P.C. Ovarian surface epithelium: biology, endocrinology, and pathology. Endocr. Rev. 22 (2001) 255-288
2. Schaner M.E., Ross D.T., Ciaravino G., Sorlie T., Troyanskaya O., Diehn M., et al. Gene expression patterns in ovarian carcinomas. Mol. Biol. Cell 14 (2003) 4376-4386
3. Welsh J.B., Zarrinkar P.P., Sapinoso L.M., Kern S.G., Behling C.A., Monk B.J., et al. Analysis of gene expression profiles in normal and neoplastic ovarian tissue samples identifies candidate molecular markers of epithelial ovarian cancer. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 1176-1181
4. Tsuchiya A., Sakamoto M., Yasuda J., Chuma M., Ohta T., Ohki M., et al. Expression profiling in ovarian clear cell carcinoma: identification of hepatocyte nuclear factor-1 beta as a molecular marker and a possible molecular target for therapy of ovarian clear cell carcinoma. Am. J. Pathol. 163 (2003) 2503-2512
5. Warrenfeltz S., Pavlik S., Datta S., Kraemer E.T., Benigno B., and McDonald J.F. Gene expression profiling of epithelial ovarian tumours correlated with malignant potential. Mol. Cancer 3 (2004) 27
6. Adib T.R., Henderson S., Perrett C., Hewitt D., Bourmpoulia D., Ledermann J., et al. Predicting biomarkers for ovarian cancer using gene-expression microarrays. Br. J. Cancer 90 (2004) 686-692
7. Bayani J., Brenton J.D., Macgregor P.F., Beheshti B., Albert M., Nallainathan D., et al. Parallel analysis of sporadic primary ovarian carcinomas by spectral karyotyping, comparative genomic hybridization, and expression microarrays. Cancer Res. 62 (2002) 3466-3476
8. Denison S.R., Becker N.A., Ferber M.J., Phillips L.A., Kalli K.R., Lee J., et al. Transcriptional profiling reveals that several common fragile-site genes are downregulated in ovarian cancer. Genes Chromosomes Cancer 34 (2002) 406-415
9. Gilks C.B., Vanderhyden B.C., Zhu S., de van Rijn M., and Longacre T.A. Distinction between serous tumors of low malignant potential and serous carcinomas based on global mRNA expression profiling. Gynecol. Oncol. 96 (2005) 684-694
10. Hibbs K., Skubitz K.M., Pambuccian S.E., Casey R.C., Burleson K.M., Oegema Jr. T.R., et al. Differential gene expression in ovarian carcinoma: identification of potential biomarkers. Am. J. Pathol. 165 (2004) 397-414
11. Jazaeri A.A., Lu K., Schmandt R., Harris C.P., Rao P.H., Sotiriou C., et al. Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma. Mol. Carcinog. 36 (2003) 53-59
12. Lancaster J.M., Dressman H.K., Whitaker R.S., Havrilesky L., Gray J., Marks J.R., et al. Gene expression patterns that characterize advanced stage serous ovarian cancers. J. Soc. Gynecol. Investig. 11 (2004) 51-59
13. Lu K.H., Patterson A.P., Wang L., Marquez R.T., Atkinson E.N., Baggerly K.A., et al. Jr., Selection of potential markers for epithelial ovarian cancer with gene expression arrays and recursive descent partition analysis. Clin. Cancer Res. 10 (2004) 3291-3300
14. Marquez R.T., Baggerly K.A., Patterson A.P., Liu J., Broaddus R., Frumovitz M., et al. Patterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colon. Clin. Cancer Res. 11 (2005) 6116-6126
15. Ono K., Tanaka T., Tsunoda T., Kitahara O., Kihara C., Okamoto A., et al. Identification by cDNA microarray of genes involved in ovarian carcinogenesis. Cancer Res. 60 (2000) 5007-5011
16. Schwartz D.R., Kardia S.L., Shedden K.A., Kuick R., Michailidis G., Taylor J.M., et al. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas. Cancer Res. 62 (2002) 4722-4729
17. Shvartsman H.S., Lu K.H., Lee J., Lillie J., Deavers M.T., Clifford S., et al. Overexpression of kallikrein 10 in epithelial ovarian carcinomas. Gynecol. Oncol. 90 (2003) 44-50
18. Smith D.I. Transcriptional profiling develops molecular signatures for ovarian tumors. Cytometry 47 (2002) 60-62
19. Wang K., Gan L., Jeffery E., Gayle M., Gown A.M., Skelly M., et al. Monitoring gene expression profile changes in ovarian carcinomas using cDNA microarray. Gene 229 (1999) 101-108
20. Chi N., and Epstein J.A. Getting your Pax straight: Pax proteins in development and disease. Trends Genet. 18 (2002) 41-47
21. Poleev A., Fickenscher H., Mundlos S., Winterpacht A., Zabel B., Fidler A., et al. PAX8, a human paired box gene: isolation and expression in developing thyroid, kidney and Wilms' tumors. Development 116 (1992) 611-623
22. Poleev A., Wendler F., Fickenscher H., Zannini M.S., Yaginuma K., Abbott C., et al. Distinct functional properties of three human paired-box-protein, PAX8, isoforms generated by alternative splicing in thyroid, kidney and Wilms' tumors. Eur. J. Biochem. 228 (1995) 899-911
23. Muratovska A., Zhou C., He S., Goodyer P., and Eccles M.R. Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival. Oncogene 22 (2003) 7989-7997
24. Macchia P.E., Lapi P., Krude H., Pirro M.T., Missero C., Chiovato L., et al. PAX8 mutations associated with congenital hypothyroidism caused by thyroid dysgenesis. Nat. Genet. 19 (1998) 83-86
25. Mansouri A., Chowdhury K., and Gruss P. Follicular cells of the thyroid gland require Pax8 gene function. Nat. Genet. 19 (1998) 87-90
26. Cotran R., Kumar V., and Robbins S. Robbins pathologic basis of disease. 5th ed. (1994), W.B. Saunders, Philadelphia
27. Kroll T.G., Sarraf P., Pecciarini L., Chen C.J., Mueller E., Spiegelman B.M., et al. PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma. [corrected]. Science 289 (2000) 1357-1360
28. Geisinger K.R., Kute T.E., Pettenati M.J., Welander C.E., Dennard Y., Collins L.A., et al. Characterization of a human ovarian carcinoma cell line with estrogen and progesterone receptors. Cancer 63 (1989) 280-288
29. Hamilton T.C., Young R.C., McKoy W.M., Grotzinger K.R., Green J.A., Chu E.W., et al. Characterization of a human ovarian carcinoma cell line (NIH:OVCAR-3) with androgen and estrogen receptors. Cancer Res. 43 (1983) 5379-5389
30. Carroll S.B. Endless forms most beautiful: the new science of evo devo (2005), W. W. Norton, New York, London
31. Gilbert S. Developmental biology. 6th ed. (2000), Sinauer Associates Inc, Sunderland, MA
32. Vainio S., Heikkila M., Kispert A., Chin N., and McMahon A.P. Female development in mammals is regulated by Wnt-4 signalling. Nature 397 (1999) 405-409
33. Kufe D., Pollock R., Weichselbaum R., Bast Jr. R., Gansler T., Holland J., et al. Cancer medicine. 6th ed. (2005), BC Decker Inc
34. Hunter R.H. The fallopian tubes in domestic mammals: how vital is their physiological activity?. Reprod. Nutr. Dev. 45 (2005) 281-290
35. Verhage H.G., Mavrogianis P.A., Boice M.L., Li W., and Fazleabas A.T. Oviductal epithelium of the baboon: hormonal control and the immuno-gold localization of oviduct-specific glycoproteins. Am. J. Anat. 187 (1990) 81-90
36. Sawyer H.R., Olson P.N., and Gorell T.A. Effects of progesterone on the oviductal epithelium in estrogen-primed prepubertal beagles: light and electron microscopic observations. Am. J. Anat. 169 (1984) 75-87
37. Bareither M.L., and Verhage H.G. Control of the secretory cell cycle in cat oviduct by estradiol and progesterone. Am. J. Anat. 162 (1981) 107-118
38. Stuart E.T., Haffner R., Oren M., and Gruss P. Loss of p53 function through PAX-mediated transcriptional repression. EMBO J. 14 (1995) 5638-5645
39. Miyashita T., and Reed J.C. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80 (1995) 293-299
40. Nutt S.L., Morrison A.M., Dorfler P., Rolink A., and Busslinger M. Identification of BSAP (Pax-5) target genes in early B-cell development by loss- and gain-of-function experiments. EMBO J. 17 (1998) 2319-2333
41. Sorenson C.M., Rogers S.A., Korsmeyer S.J., and Hammerman M.R. Fulminant metanephric apoptosis and abnormal kidney development in bcl-2-deficient mice. Am. J. Physiol. 268 (1995) F73-F81
42. Hewitt S.M., Hamada S., Monarres A., Kottical L.V., Saunders G.F., and McDonnell T.J. Transcriptional activation of the bcl-2 apoptosis suppressor gene by the paired box transcription factor PAX8. Anticancer Res. 17 (1997) 3211-3215
43. Piek J.M., van Diest P.J., Verheijen R.H., and Kenemans P. Cell cycle-related proteins p21 and bcl-2: markers of differentiation in the human fallopian tube. Histopathology 38 (2001) 481-482
44. Finch A., Shaw P., Rosen B., Murphy J., Narod S.A., and Colgan T.J. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol. Oncol. 100 (2006) 58-64
45. Medeiros F., Muto M.G., Lee Y., Elvin J.A., Callahan M.J., Feltmate C., et al. The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome. Am. J. Surg. Pathol. 30 (2006) 230-236